These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
253 related articles for article (PubMed ID: 32066439)
1. Impact of polyunsaturated fatty acids on patient-important outcomes in children and adolescents with autism spectrum disorder: a systematic review. De Crescenzo F; D'Alò GL; Morgano GP; Minozzi S; Mitrova Z; Saulle R; Cruciani F; Fulceri F; Davoli M; Scattoni ML; Nardocci F; Schünemann HJ; Amato L; Health Qual Life Outcomes; 2020 Feb; 18(1):28. PubMed ID: 32066439 [TBL] [Abstract][Full Text] [Related]
2. Impact of antipsychotics in children and adolescents with autism spectrum disorder: a systematic review and meta-analysis. D'Alò GL; De Crescenzo F; Amato L; Cruciani F; Davoli M; Fulceri F; Minozzi S; Mitrova Z; Morgano GP; Nardocci F; Saulle R; Schünemann HJ; Scattoni ML; Health Qual Life Outcomes; 2021 Jan; 19(1):33. PubMed ID: 33494757 [TBL] [Abstract][Full Text] [Related]
3. Equity, acceptability and feasibility of using polyunsaturated fatty acids in children and adolescents with autism spectrum disorder: a rapid systematic review. D'Alò GL; De Crescenzo F; Minozzi S; Morgano GP; Mitrova Z; Scattoni ML; Amato L; Davoli M; Schünemann HJ; Health Qual Life Outcomes; 2020 Apr; 18(1):101. PubMed ID: 32299432 [TBL] [Abstract][Full Text] [Related]
4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas. Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557 [TBL] [Abstract][Full Text] [Related]
6. The effectiveness and adverse effects of D-cycloserine compared with placebo on social and communication skills in individuals with autism spectrum disorder. Aye SZ; Ni H; Sein HH; Mon ST; Zheng Q; Wong YKY Cochrane Database Syst Rev; 2021 Feb; 2(2):CD013457. PubMed ID: 33583058 [TBL] [Abstract][Full Text] [Related]
7. Acetylcholinesterase inhibitors for autistic spectrum disorders. Ure A; Cox GR; Haslam R; Williams K Cochrane Database Syst Rev; 2023 Jun; 6(6):CD013851. PubMed ID: 37267443 [TBL] [Abstract][Full Text] [Related]
8. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Storebø OJ; Storm MRO; Pereira Ribeiro J; Skoog M; Groth C; Callesen HE; Schaug JP; Darling Rasmussen P; Huus CL; Zwi M; Kirubakaran R; Simonsen E; Gluud C Cochrane Database Syst Rev; 2023 Mar; 3(3):CD009885. PubMed ID: 36971690 [TBL] [Abstract][Full Text] [Related]
10. Polyunsaturated fatty acids (PUFA) for attention deficit hyperactivity disorder (ADHD) in children and adolescents. Gillies D; Leach MJ; Perez Algorta G Cochrane Database Syst Rev; 2023 Apr; 4(4):CD007986. PubMed ID: 37058600 [TBL] [Abstract][Full Text] [Related]
11. Pharmacological and dietary-supplement treatments for autism spectrum disorder: a systematic review and network meta-analysis. Siafis S; Çıray O; Wu H; Schneider-Thoma J; Bighelli I; Krause M; Rodolico A; Ceraso A; Deste G; Huhn M; Fraguas D; San José Cáceres A; Mavridis D; Charman T; Murphy DG; Parellada M; Arango C; Leucht S Mol Autism; 2022 Mar; 13(1):10. PubMed ID: 35246237 [TBL] [Abstract][Full Text] [Related]
12. Behavioural and cognitive behavioural therapy for obsessive compulsive disorder (OCD) in individuals with autism spectrum disorder (ASD). Elliott SJ; Marshall D; Morley K; Uphoff E; Kumar M; Meader N Cochrane Database Syst Rev; 2021 Sep; 9(9):CD013173. PubMed ID: 34693989 [TBL] [Abstract][Full Text] [Related]
13. Atypical antipsychotics for disruptive behaviour disorders in children and youths. Loy JH; Merry SN; Hetrick SE; Stasiak K Cochrane Database Syst Rev; 2017 Aug; 8(8):CD008559. PubMed ID: 28791693 [TBL] [Abstract][Full Text] [Related]
14. Music therapy for people with autism spectrum disorder. Geretsegger M; Elefant C; Mössler KA; Gold C Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD004381. PubMed ID: 24936966 [TBL] [Abstract][Full Text] [Related]
15. Communication interventions for autism spectrum disorder in minimally verbal children. Brignell A; Chenausky KV; Song H; Zhu J; Suo C; Morgan AT Cochrane Database Syst Rev; 2018 Nov; 11(11):CD012324. PubMed ID: 30395694 [TBL] [Abstract][Full Text] [Related]
16. Early intensive behavioral intervention (EIBI) for young children with autism spectrum disorders (ASD). Reichow B; Hume K; Barton EE; Boyd BA Cochrane Database Syst Rev; 2018 May; 5(5):CD009260. PubMed ID: 29742275 [TBL] [Abstract][Full Text] [Related]
17. Polyunsaturated fatty acids (PUFA) for attention deficit hyperactivity disorder (ADHD) in children and adolescents. Gillies D; Sinn JKh; Lad SS; Leach MJ; Ross MJ Cochrane Database Syst Rev; 2012 Jul; 2012(7):CD007986. PubMed ID: 22786509 [TBL] [Abstract][Full Text] [Related]
18. Atypical antipsychotics for disruptive behaviour disorders in children and youths. Loy JH; Merry SN; Hetrick SE; Stasiak K Cochrane Database Syst Rev; 2012 Sep; (9):CD008559. PubMed ID: 22972123 [TBL] [Abstract][Full Text] [Related]
19. Atomoxetine for attention deficit hyperactivity disorder in children and adolescents with autism: A systematic review and meta-analysis. Patra S; Nebhinani N; Viswanathan A; Kirubakaran R Autism Res; 2019 Apr; 12(4):542-552. PubMed ID: 30653855 [TBL] [Abstract][Full Text] [Related]